Last Update 26 Mar 26

IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating

Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53.

Analyst Commentary

Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay. Bullish analysts have adjusted their models, resulting in price targets lifted by double digit dollar amounts, and are framing their views around how consistently the company can execute against these assumptions.

Bullish Takeaways

Bullish analysts view the fair value of US$120 and future P/E of 58.53 as justified by the current revenue growth assumption of 9.70% and a profit margin assumption of 27.77%, arguing that the combination of growth and profitability supports a premium multiple.
They highlight that the detailed valuation work, including a 7.69% discount rate, reflects a structured approach to risk and cash flow timing, which they see as supportive of higher price targets raised by double digit amounts.
The uplift in price targets by US$20 and US$22 is framed as a response to refined modeling rather than a single event. Bullish analysts see this as a sign that the story is backed by more granular assumptions on growth and margins.
Supporters of the higher valuation argue that the assumed profit margin of 27.77% provides room for the company to absorb some cost pressure while still meeting the earnings profile embedded in the future P/E of 58.53.

Bearish Takeaways

Bearish analysts focus on the future P/E of 58.53 as demanding, cautioning that the shares need consistent delivery on the 9.70% revenue growth assumption and 27.77% profit margin to support such a rich multiple.
They point out that the 7.69% discount rate is a key swing factor in the US$120 fair value, and that changes in perceived risk or funding costs could have an outsized impact on valuation if assumptions need to be revisited.
There is concern that price targets raised by double digit amounts compress the margin for error. Any shortfall versus the modeled growth or profitability path could translate quickly into pressure on the current valuation framework.
Cautious voices stress that while the updated models are detailed, the combination of a high implied P/E and specific growth and margin assumptions leaves less room for unexpected execution issues without affecting the fair value estimate.

What's in the News

The board of directors declared a regular quarterly cash dividend of $0.20 per share of outstanding common stock, payable on March 6, 2026, to stockholders of record as of February 23, 2026 (Key Developments).
The company issued earnings guidance for Q1 2026 with expected revenue in the range of $21.0 million to $22.0 million and GAAP diluted EPS between $0.39 and $0.43 (Key Developments).
The company provided full-year 2026 guidance, expecting revenue in the range of $91.0 million to $96.0 million and GAAP diluted EPS between $1.90 and $2.05 (Key Developments).

Valuation Changes

Fair Value: The fair value estimate remains at $120.0, effectively unchanged from the prior $120 figure.
Discount Rate: The discount rate has shifted slightly from 7.688535% to 7.689752392381835%, a very small adjustment in the model's risk input.
Revenue Growth: The long term revenue growth assumption is essentially unchanged at 9.696329048255103%, compared with 9.696329% previously.
Net Profit Margin: The profit margin input remains steady at 27.77013718904308%, versus 27.770137% in the earlier model.
Future P/E: The future P/E assumption has moved marginally from 58.532897x to 58.5348825717802x, reflecting a very small model refinement.

1 view

Key Takeaways

Enhanced usability and technology in the new MRI-compatible IV pump are expected to drive major replacement cycles and expand the customer base.
Aging populations and higher MRI volumes support sustained demand, while operational investments and strong pricing power boost margins and revenue visibility.
Heavy reliance on a narrow product range and domestic growth, combined with supply chain, innovation, and operational risks, threatens long-term stability and competitive positioning.

Catalysts

About IRADIMED

Develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally.What are the underlying business or industry changes driving this perspective?

The introduction and FDA approval of the new 3870 MRI-compatible IV pump, with significantly enhanced usability and technology over the legacy product, is expected to catalyze a major replacement cycle among hospitals and imaging centers, unlocking large-scale, recurring device and consumable revenues. This supports a step-change in revenue growth as existing customers upgrade and potential new customers previously deterred by usability issues are attracted.
The broadened addressable market due to user-friendly advancements in the 3870 is likely to convert fence sitters that delayed or avoided prior adoption-supporting both market share gains and incremental revenue expansion beyond just the replacement cycle.
An aging global population and rising chronic disease incidence are driving ongoing increases in MRI procedure volumes, which in turn sustains and enhances long-term demand for MRI-safe infusion pumps and monitoring devices, supporting durable multiyear revenue and earnings growth.
The pricing power associated with the new 3870 pump-management expects a ~12% higher average selling price than the older model-should directly support higher gross margins, while the company's demonstrated ability to maintain ~78% gross margin yields operating leverage, boosting both net margins and earnings per share as the business scales.
Recent and ongoing investments in new manufacturing facilities and inventory, plus a record order backlog, provide improved operational capacity and strong near-term revenue visibility, supporting healthy cash flows and strengthening the ability to fund further innovation and market expansion initiatives.

IRADIMED Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming IRADIMED's revenue will grow by 9.7% annually over the next 3 years.
Analysts assume that profit margins will increase from 26.8% today to 27.8% in 3 years time.
Analysts expect earnings to reach $30.7 million (and earnings per share of $2.35) by about March 2029, up from $22.5 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 63.3x on those 2029 earnings, up from 57.9x today. This future PE is greater than the current PE for the US Medical Equipment industry at 27.6x.
Analysts expect the number of shares outstanding to grow by 0.53% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.69%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Heavy dependence on the MRI-compatible IV pump and monitor product lines increases concentration risk; if technological advances or superior alternatives reduce the need for specialized pumps, IRADIMED's revenues and future earnings could be materially impacted.
Continued cost pressures on global healthcare providers-demonstrated by the company's primary revenue growth stemming from domestic markets-could limit hospitals' capital expenditures and slow adoption of IRADIMED devices internationally, threatening long-term revenue growth and margin expansion.
Ongoing and potential future tariffs on key components, especially as pre-tariff inventory is depleted and global trade tensions persist, may elevate input costs and compress gross margins as IRADIMED has limited flexibility in its existing supply chain.
Limited R&D spend and a narrow product portfolio-evidenced by modest research expenses despite facility expansion-could constrain innovation and the company's ability to respond rapidly to rising competition or tightening regulatory requirements, negatively affecting long-term competitive position and earnings.
The extended backlog fulfillment timeline (5–6 months for pumps) and slow ramp-up for the new 3870 device exposes IRADIMED to operational execution risk; any supply chain disruption, regulatory setback, or delayed customer conversion could result in revenue volatility and earnings pressure in transition years.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $120.0 for IRADIMED based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $110.6 million, earnings will come to $30.7 million, and it would be trading on a PE ratio of 63.3x, assuming you use a discount rate of 7.7%.
Given the current share price of $101.78, the analyst price target of $120.0 is 15.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on IRADIMED?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

IRMD: Index Addition and Strong Margins Will Support Measured Upside